The early termination of clinical trials: causes, consequences, and control. With special reference to trials in the field of arrhythmias and sudden death. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology.
暂无分享,去创建一个
Ralph Lazzara | Peter J. Schwartz | Curt D. Furberg | David L. DeMets | Günter Breithardt | Arthur J. Moss | Alfred P. Hallstrom | A. John Camm | Michiel J. Janse | J. Thomas Bigger | Albert L. Waldo | D. DeMets | G. Breithardt | A. Camm | S. Pocock | C. Furberg | J. Bigger | A. Moss | P. Schwartz | R. Lazzara | A. Hallstrom | M. Janse | A. Waldo | F. Marcus | D. Julian | J. Tijssen | Stuart J. Pocock | Desmond G. Julian | Frank I. Marcus | Jan G.P. Tijssen | Kuang Kuo Gordon Lan | K. K. Lan
[1] P. Canner. Monitoring treatment differences in long-term clinical trials. , 1977, Biometrics.
[2] Practical aspects of decision making in clinical trials: the coronary drug project as a case study. The Coronary Drug Project Research Group. , 1981, Controlled clinical trials.
[3] D L DeMets,et al. Changing frequency of interim analysis in sequential monitoring. , 1989, Biometrics.
[4] R. Cappato,et al. ICD versus Drugs in Cardiac Arrest Survivors: Preliminary Results of the Cardiac Arrest Study Hamburg , 1993, Pacing and clinical electrophysiology : PACE.
[5] David L. DeMets,et al. Group sequential methods for clinical trials with a one-sided hypothesis , 1980 .
[6] Y Pawitan,et al. Statistical interim monitoring of the Cardiac Arrhythmia Suppression Trial. , 1990, Statistics in medicine.
[7] J. Ruskin,et al. The cardiac arrhythmia suppression trial (CAST). , 1989, The New England journal of medicine.
[8] K. K. Lan,et al. Discrete sequential boundaries for clinical trials , 1983 .
[9] J. Ruskin,et al. Data monitoring in the cardiac arrhythmia suppression trial. , 1993, The Online journal of current clinical trials.
[10] D L Demets,et al. Practical aspects in data monitoring: a brief review. , 1987, Statistics in medicine.
[11] J. Haybittle,et al. Repeated assessment of results in clinical trials of cancer treatment. , 1971, The British journal of radiology.
[12] M. Weir,et al. The Cardiac Arrhythmia Suppression Trial Investigators: Preliminary Report: Effect of Encainide and Flecainide on Mortality in a Randomized Trial of Arrhythmia Suppression After Myocardial Infarction. , 1990 .
[13] D L DeMets,et al. Statistical aspects of early termination in the beta-blocker heart attack trial. , 1982, Controlled clinical trials.
[14] P. O'Brien,et al. A multiple testing procedure for clinical trials. , 1979, Biometrics.
[15] B. Turnbull,et al. Repeated confidence intervals for group sequential clinical trials. , 1984, Controlled clinical trials.
[16] S. Pocock. Group sequential methods in the design and analysis of clinical trials , 1977 .
[17] Aims Trial Study Group. EFFECT OF INTRAVENOUS APSAC ON MORTALITY AFTER ACUTE MYOCARDIAL INFARCTION: PRELIMINARY REPORT OF A PLACEBO-CONTROLLED CLINICAL TRIAL , 1988, The Lancet.
[18] P. Armitage,et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. , 1976, British Journal of Cancer.
[19] Anastasios A. Tsiatis,et al. Repeated Significance Testing for a General Class of Statistics Used in Censored Survival Analysis , 1982 .
[20] D. DeMets,et al. The randomized clinical trial: bias in analysis. , 1981, Circulation.
[21] D. Zucker,et al. Sequential monitoring of clinical trials: the role of information and Brownian motion. , 1993, Statistics in medicine.
[22] K. K. Lan,et al. Stochastically curtailed tests in long–term clinical trials , 1982 .
[23] Christopher Jennison,et al. Interim analyses: the repeated confidence interval approach , 1989 .
[24] Sulfinpyrazone in the prevention of cardiac death after myocardial infarction. The Anturane Reinfarction Trial. , 1978, The New England journal of medicine.
[25] G. Pledger,et al. The FDA's critique of the anturane reinfarction trial. , 1980, The New England journal of medicine.
[26] A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. , 1982, JAMA.
[27] S. Pocock,et al. When to stop a clinical trial. , 1992, BMJ.
[28] A. Camm,et al. CAST and beyond. Implications of the Cardiac Arrhythmia Suppression Trial. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology. , 1990, Circulation.
[29] Anna C. Balazs,et al. Influence of adherence to treatment and response of cholesterol on mortality in the coronary drug project. , 1980, The New England journal of medicine.
[30] K K Lan,et al. The B-value: a tool for monitoring data. , 1988, Biometrics.
[31] David L. DeMets,et al. Asymmetric group sequential boundaries for monitoring clinical trials , 1982 .
[32] D L Demets,et al. Group sequential procedures: calendar versus information time. , 1989, Statistics in medicine.
[33] J. Fleiss,et al. Mechanism of death and prevalence of myocardial ischemic symptoms in the terminal event after acute myocardial infarction. , 1988, The American journal of cardiology.
[34] P. Armitage,et al. Repeated Significance Tests on Accumulating Data , 1969 .